![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, June 10, 2016 3:32:24 PM
Nonetheless, that still does not address what may be the bigger question about the competitive market. I have said this before but for all the new posters reading, the message bears repeating because it makes clear we are NOT talking about a declining market but a growth market and here is the logic...
...We know from the demographic and global consumer changes occurring that the market for pain meds, in general, and opioids, in particular, will see sustainable growth for the next ten years, at least. And, as has been noted, the socio-political-legal-regulatory aspects of the external environment will only serve to make the market more competitive, not less. That competition will be governed by a move to ADFs (abuse deterrent formulations); which will form a future barrier to market entry. While there remains some debate as to what the percentage of ADFs are currently in the market, it appears to be no higher than 11%. Moreover, the current market leader, Purdue, is struggling with legal issues that directly threaten its 28% share of the market - less with an ADF tipping point.
So, what we can glean from the above? It is that the opioid pain med market remains the Wild West of pharma opportunity. With ADFs set to form a tipping point and no single company in control with a sizable share of ADFs in the market, it remains that there exists an opportunity that does not require a best-in-class product to compete; a point made clear with Mannkind and its diabetes drug Afrezza. However, in the Wild West opioid pain med market, ADFs of all kinds will gain footing (until they prove to be ineffective or priced poorly) and there will be no reason to believe that Elite, with an FDA approved tech that can be used on a range of drugs, will not capture a notable share of the market. In fact, if we consider a key statement in the FDA April 2015 guidance we will see some interesting points in the following (on page 2 of the following link…http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm440713.htm. It states…”The FDA intends on taking a flexible adaptive approach to the evaluation and labeling of potentially abuse deterrent products.” They go on to say…”The FDA intends to consider the totality of the evidence (their emphasis) when reviewing the results of studies evaluating the abuse deterrent properties of a product.” Sounds like there is no one way the FDA is looking to crown a single abuse deterrent product/approach. I guess that is why Acura, Collegium, Pfizer and even Purdue have or are close to having approved abuse deterrent products. They are all very different, with none noted by the FDA as a gold standard, suggesting that others may enter the competition if they are within the seven product areas identified.
Based on the positive data from their P-3 and granted a priority review, it appears Elite will soon be competing in a changing and growing market. Now, whether a big pharma firm wants to buy Elite because they have a proof of concept is another matter. One might say that, in light of the slow growth for pharma, more consolidation (M&A) is likely and I would be fine with Elite's BOD accepting a well priced offer. But "to unload" is such a pejorative term and an action that would be deleterious to we investors. I much prefer a negotiated sale.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:07:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2023 08:15:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 09:30:05 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 07/31/2023 08:20:27 PM
FEATURED Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • Jul 29, 2024 9:07 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM